Click on the company or penalty amount for more information on each case. Click on the current parent name to reach the summary page for that parent company.
Company | Current Parent | Current Parent Industry | Primary Offense Type | Year | Agency | Penalty Amount |
---|---|---|---|---|---|---|
Genentech | Roche | pharmaceuticals | hazardous waste violation | 2023 | EPA | $158,208 |
SCHERING-PLOUGH PRODUCTS LLC | Merck | pharmaceuticals | hazardous waste violation | 2001 | EPA | $54,100 |
SEARLE LTD | Pfizer | pharmaceuticals | hazardous waste violation | 2002 | EPA | $95,000 |
Schering Plough Products | Merck | pharmaceuticals | hazardous waste violation | 2002 | EPA | $49,000 |
Lilly Del Caribe, Inc. | Eli Lilly | pharmaceuticals | hazardous waste violation | 2003 | EPA | $68,992 |
Wyeth Ayerst Pharmaceuticals | Pfizer | pharmaceuticals | hazardous waste violation | 2004 | EPA | $37,000 |
Pfizer Pharmaceuticals LLC | Pfizer | pharmaceuticals | hazardous waste violation | 2005 | EPA | $55,000 |
Merck Sharp & Dohme Quimica de Puerto Rico | Merck | pharmaceuticals | hazardous waste violation | 2007 | EPA | $10,000 |
Bristol Myers Squibb Manufacturing Company | Bristol-Myers Squibb | pharmaceuticals | hazardous waste violation | 2008 | EPA | $52,000 |
Roche Molecular Systems, Inc. | Roche | pharmaceuticals | hazardous waste violation | 2011 | EPA | $90,000 |
Teva Pharmaceuticals USA, Inc. | Teva Pharmaceutical Industries | pharmaceuticals | hazardous waste violation | 2003 | EPA | $61,158 |
GLAXOSMITHKLINE, LLC | GlaxoSmithKline | pharmaceuticals | hazardous waste violation | 2014 | EPA | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $317,550 |
IMO SANOFI PASTEUR | Sanofi | pharmaceuticals | hazardous waste violation | 2014 | EPA | $77,643 |
VERSUM MATERIALS, INC. | Merck KGaA (EMD) | pharmaceuticals | hazardous waste violation | 2020 | EPA | $17,600 |
MERCK SHARP & DOHME CORP. | Merck | pharmaceuticals | hazardous waste violation | 2023 | EPA | $6,250 |
research organics | Merck KGaA (EMD) | pharmaceuticals | hazardous waste violation | 2003 | EPA | $159,672 |
Phibro-Tech, Inc. | Phibro Animal Health | pharmaceuticals | hazardous waste violation | 2008 | EPA | $151,603 |
ACTAVIS,INC. | AbbVie | pharmaceuticals | hazardous waste violation | 2015 | EPA | $30,800 |
Aldrich Chemical | Merck KGaA (EMD) | pharmaceuticals | hazardous waste violation | 2018 | EPA | $5,000 |
Aldrich Chemical, LLC | Merck KGaA (EMD) | pharmaceuticals | hazardous waste violation | 2018 | EPA | $5,000 |
CAMBREX CHARLES CITY, INC | Cambrex | pharmaceuticals | hazardous waste violation | 2006 | EPA | $106,749 |
ABBOTT LABORATORIES | Abbott Laboratories | pharmaceuticals | hazardous waste violation | 2008 | EPA | $25,033 |
BOEHRINGER INGELHEIM VETMEDICA, INC | Eli Lilly | pharmaceuticals | hazardous waste violation | 2012 | EPA | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $338,475 |
MALLINCKRODT, LLC | Mallinckrodt | pharmaceuticals | hazardous waste violation | 2013 | EPA | $449,740 |
DePuy Synthes | Johnson & Johnson | pharmaceuticals | hazardous waste violation | 2019 | EPA | $51,750 |
Amgen Inc. | Amgen | pharmaceuticals | hazardous waste violation | 2007 | EPA | $24,368 |
Glenmark Pharmaceuticals, Inc. | Glenmark Pharmaceuticals | pharmaceuticals | HHS civil monetary penalties | 2015 | HHSOIG | $2,887,300 |
Sandoz, Inc. | Sandoz Group | pharmaceuticals | HHS civil monetary penalties | 2015 | HHSOIG | $12,640,000 |
Sandoz, Inc. | Sandoz Group | pharmaceuticals | HHS civil monetary penalties | 2011 | HHSOIG | $230,000 |
Valeant Pharmaceuticals, Inc. | Bausch Health | pharmaceuticals | insurance violation | 2018 | CA-INS | $1,875,000 |
Johnson & Johnson, Inc. | Johnson & Johnson | pharmaceuticals | insurance violation | 2020 | NC-INS | $150,000 |
Schering-Plough Corporation | Merck | pharmaceuticals | investor protection violation | 2003 | SEC | $1,000,000 |
Allergan Inc. | AbbVie | pharmaceuticals | investor protection violation | 2017 | SEC | $15,000,000 |
Aegerion Pharmaceuticals | Amryt Pharma | pharmaceuticals | investor protection violation | 2017 | SEC | $4,100,000 |
Cytrx Corporation | CytRx | pharmaceuticals | investor protection violation | 2017 | SEC | $75,000 |
Clovis Oncology Inc. | Clovis Oncology | pharmaceuticals | investor protection violation | 2018 | SEC | $20,000,000 |
Mylan N.V. | Viatris | pharmaceuticals | investor protection violation | 2019 | SEC | $30,000,000 |
Amyris, Inc. | Amyris | pharmaceuticals | investor protection violation | 2021 | SEC | $300,000 |
St. Jude Medical Inc. | Abbott Laboratories | pharmaceuticals | kickbacks and bribery | 2011 | DOJ_CIVIL | $16,000,000 |
Kos Pharmaceuticals | AbbVie | pharmaceuticals | kickbacks and bribery | 2010 | FDA | $41,500,000 |
Novartis Pharmaceuticals | Novartis | pharmaceuticals | kickbacks and bribery | 2015 | USAO | $390,000,000 |
Novo Nordisk A/S | Novo Holdings A/S | pharmaceuticals | kickbacks and bribery | 2009 | DOJ_CRIMINAL | $9,000,000 |
AstraZeneca PLC | AstraZeneca | pharmaceuticals | kickbacks and bribery | 2016 | SEC | $5,522,000 |
GlaxoSmithKline plc | GlaxoSmithKline | pharmaceuticals | kickbacks and bribery | 2016 | SEC | $20,000,000 |
Pharmacia & Upjohn Company Inc. | Pfizer | pharmaceuticals | kickbacks and bribery | 2007 | USAO | $19,700,000 |
Pharmacia & Upjohn Company LLC | Pfizer | pharmaceuticals | kickbacks and bribery | 2007 | USAO | $15,000,000 |
AbbVie Inc. | AbbVie | pharmaceuticals | kickbacks and bribery | 2018 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $1,800,000 |
Alere Inc. | Abbott Laboratories | pharmaceuticals | kickbacks and bribery | 2017 | MS-AG | $2,000,000 |
Kos Pharmaceuticals | AbbVie | pharmaceuticals | kickbacks and bribery | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $4,454,432 |
Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | kickbacks and bribery | 2015 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $83,129,754 |
Pfizer, Inc. | Pfizer | pharmaceuticals | kickbacks and bribery | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $331,485,170 |
TAP Pharmaceutical Products, Inc. | Takeda Pharmaceutical | pharmaceuticals | kickbacks and bribery | 2006 | KY-AG | $600,000 |
TAP Pharmaceutical Products, Inc. | Takeda Pharmaceutical | pharmaceuticals | kickbacks and bribery | 2006 | WI-AG | $798,000 |
Teva Pharmaceuticals USA Inc. | Teva Pharmaceutical Industries | pharmaceuticals | kickbacks and bribery | 2014 | IL-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $12,100,000 |
Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | kickbacks and bribery | 2016 | CA-INS | $30,000,000 |
Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | kickbacks and bribery | 2020 | CA-AG | $11,800,000 |
Novartis Pharmaceuticals Corp. | Novartis | pharmaceuticals | kickbacks and bribery | 2020 | MULTI-AG | $103,000,000 |
Pacira Pharmaceuticals, Inc. | Pacira BioSciences | pharmaceuticals | kickbacks and bribery | 2020 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $3,500,000 |
Parexel International, LLC | Parexel International | pharmaceuticals | labor relations violation | 2012 | NLRB | $253,000 |
Amgen, Inc. | Amgen | pharmaceuticals | labor relations violation | 2011 | NLRB | $40,000 |
Merck and Company, Inc. | Merck | pharmaceuticals | labor relations violation | 2009 | NLRB | $10,710 |
Merck & Co., Inc. | Merck | pharmaceuticals | labor relations violation | 2008 | NLRB | $100,000 |
Schering-Plough | Merck | pharmaceuticals | labor relations violation | 2007 | NLRB | $8,200 |
Boehringer Ingelheim Pharmaceutical, Inc. | Boehringer Ingelheim | pharmaceuticals | labor relations violation | 2004 | NLRB | $50,000 |
Advanced Medical Optics | Abbott Laboratories | pharmaceuticals | labor relations violation | 2004 | NLRB | $16,800 |
Therasense, Inc. | Abbott Laboratories | pharmaceuticals | labor relations violation | 2003 | NLRB | $236,827 |
Actavis Kadian, LLC | AbbVie | pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $116,703 |
Intermune, Inc. | Roche | pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $5,641 |
Intermune, Inc. | Roche | pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $16,215 |
Amneal Pharmaceutical, LLC | Amneal Pharmaceuticals | pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2015 | CMS | $5,909 |
Amneal Pharmaceutical, LLC | Amneal Pharmaceuticals | pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2015 | CMS | $9,440 |
Amneal Pharmaceutical, LLC | Amneal Pharmaceuticals | pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2016 | CMS | $10,788 |
Amneal Pharmaceuticals, LLC | Amneal Pharmaceuticals | pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2016 | CMS | $12,367 |
Amneal Pharmaceuticals, LLC | Amneal Pharmaceuticals | pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2019 | CMS | $12,968 |
Wockhardt USA | Wockhardt Limited | pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2020 | CMS | $111,824 |
Alnylam Pharmaceuticals, Inc. | Alnylam Pharmaceuticals | pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2023 | CMS | $31,959 |
CAMBRIDGE MAJOR LABORATORIES INC | Alcami | pharmaceuticals | motor vehicle safety violation | 2006 | FMCSA | $18,560 |
EMD CHEMICALS INCORPORATED | Merck KGaA (EMD) | pharmaceuticals | motor vehicle safety violation | 2006 | FMCSA | $7,614 |
CAMBRIDGE MAJOR LABORATORIES INC | Alcami | pharmaceuticals | motor vehicle safety violation | 2005 | FMCSA | $15,820 |
EMD CHEMICALS INCORPORATED | Merck KGaA (EMD) | pharmaceuticals | motor vehicle safety violation | 2004 | FMCSA | $13,170 |
Cody Laboratories Inc | Lannett Co. | pharmaceuticals | motor vehicle safety violation | 2018 | FMCSA | $8,510 |
Mallinckrodt, Inc. | Mallinckrodt | pharmaceuticals | nuclear safety violation | 2000 | NRC | $125,000 |
Endo Health Solutions Inc. | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | FDA | $192,700,000 |
Wyeth Pharmaceuticals Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | FDA | $490,900,000 |
Par Pharmaceutical Companies Inc. | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | FDA | $45,000,000 |
Abbott Laboratories Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $1,500,000,000 |
Cypress Pharmaceutical Inc. | Currax Pharmaceuticals | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $2,800,000 |
Merck, Sharp & Dohme | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $950,000,000 |
Pfizer Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $14,500,000 |
Scios Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $85,000,000 |
UCB Inc. | UCB | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $34,000,000 |
Forest Pharmaceuticals Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $164,000,000 |
Elan Corporation PLC | Perrigo | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $203,000,000 |
Eisai Inc. | Eisai | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $11,000,000 |
Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $422,500,000 |
Allergan Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $600,000,000 |
Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $81,000,000 |
AstraZeneca LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $520,000,000 |
Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $762,000,000 |
Warner Chilcott PLC | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | FDA | $125,000,000 |
Boehringer Ingelheim Pharmaceuticals Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $95,000,000 |